Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma.

The Journal of investigative dermatology - 1 Oct 2025

Su Liya, Wang Dinghao, Purwin Timothy J, Ran Sophia, Yang Qi, Zhang Qingrun, Cai Weijia

Abstract excerpt

Targeted therapy for NRAS-mutant melanoma remains an unmet clinical need. We found that inhibiting USP7 with the selective ubiquitin-specific protease 7 inhibitor (USP7i) FT671 inhibited cell proliferation in NRAS-mutant melanoma cell lines. In addition, we identified and validated that knockout of TP53BP1, TP53, or CDKN1A conferred resistance to FT671, suggesting that the activation of a functional p53 signaling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Monomeric GTP-Binding Proteins

Share to Programmed Cell Death 1 Receptor

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40204067
DOI: 10.1016/j.jid.2025.03.021
PMCID: PMC12354106

Genes

NRAS
USP7
CDKN1A
TP53
TP53BP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective USP7 Inhibition Synergizes with MEK1/2 Inhibitor to Enhance Immune Responses and Potentiate Anti-PD-1 Therapy in NRAS-Mutant Melanoma.PMID 40204067Read ↗

Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting TherapiesSemantic proximity Read ↗

USP22 deficiency in melanoma mediates resistance to T cells through IFNγ-JAK1-STAT1 signal axisSemantic proximity Read ↗

Pharmacological targeting of casein kinase 1δ suppresses oncogenic NRAS-driven melanoma.Semantic proximity Read ↗

Up‐regulated deubiquitinase USP 4 plays an oncogenic role in melanomaSemantic proximity Read ↗

Deubiquitinating enzyme USP48 mediates pyroptosis and meliorates immune evasion in tumors by stabilizing GSDME expressionSemantic proximity Read ↗

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity Read ↗

Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment.Semantic proximity Read ↗

Usp8 promotes tumor cell migration through activating the JNK pathwaySemantic proximity Read ↗

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.Semantic proximity Read ↗

USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.Semantic proximity Read ↗

Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers.Semantic proximity Read ↗

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.